Capstone Investment Advisors
ALLO icon

Capstone Investment Advisors’s Allogene Therapeutics ALLO Stock Holding History

Capstone Investment Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-21,438
Closed -$107K – 2091
2023
Q2 		$107K Buy
+21,438
New +$116K ﹤0.01% 1688

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capstone Investment Advisors's ALLO Position: Q3 2023 in Review

Capstone Investment Advisors sold out of Allogene Therapeutics (ALLO) in Q3 2023, closing a stake of 21,438 shares — an estimated $107K sold.

Capstone Investment Advisors first reported a position in ALLO in Q2 2023 and held it in 1 quarter. The position peaked at $107K in Q2 2023. 154 funds tracked by Wall St. Rank hold ALLO as of Q3 2023.

  • Capstone Investment Advisors reported no remaining Allogene Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Capstone Investment Advisors sold 21,438 Allogene Therapeutics shares in Q3 2023, an estimated $107K.
  • Capstone Investment Advisors first reported a position in Allogene Therapeutics in Q2 2023 and held it in 1 quarter.
  • Capstone Investment Advisors's Allogene Therapeutics position peaked at $107K in Q2 2023.
  • 154 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2023.

Based on Capstone Investment Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.